Sign in
CompletedPhase 1

Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1
People taking part
5 people enrolled
Started
13 Mar 2024
Ended
18 Feb 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • [11C]-PHNO
  • Calcitriol
  • Placebo Control
  • PET Scan
Record updated
14 November 2025

Who can take part

Age
18 years to 50 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • Age 18-50 years
  • Voluntary, written, informed consent
  • Physically healthy by medical history, physical, neurological, ECG, and laboratory examinations
  • Meets the criteria for OUD, as determined by the Structured Clinical Interview for DSM-5 (SCID)
  • Stable and receiving buprenorphine treatment for OUD
  • For females, non-lactating, with a negative serum or urine pregnancy (hCG) test
  • Lab results without clinically relevant findings (e.g., renal function, electrolytes, and vitamin D levels)
  • English speaking

Who cannot take part

  • Positive answers on the cardiac history questionnaire that may place the subject at higher risk, as determined by the study physician's review of both the questionnaire responses and screening ECG. If there is concern for the subject's safety due to these assessments, research staff will consult a Yale PET Center affiliated cardiologist prior to including the subject for the study
  • Current use of psychotropic and/or potentially psychoactive prescription medications
  • Receiving medications for OUD other than buprenorphine (e.g., methadone treatment)
  • MRI-incompatible implants and other contraindications for MRI (i.e., aneurysm clip, metal fragments, internal electrical devices such as a cochlear implant, spinal cord stimulator or pacemaker)
  • Donation or loss of 550 mL of blood or more (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to the first test day
  • Use of any prescription medications and/or over-the-counter medications, vitamins and/or herbal supplements which could have a negative clinical interaction with calcitriol or which could confound scientific results of the study, within 2 weeks prior to each test day (e.g., thiazide diuretics, Mg based antiacids, digoxin, etc,)
  • Subjects with history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure. This guideline is an effective dose of 5 rem received per year
  • Subjects with current, past or anticipated exposure to radiation in the workplace
  • Medical contraindication to calcitriol administration (e.g., history of hypersensitivity to calcitriol or any component of the formulation, hypercalcemia or vitamin D toxicity)
  • History of substance dependence (e.g., alcohol, sedative hypnotics), except for nicotine and opiates
  • A primary major DSM-5 psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) as determined by the SCID, except for Opioid Use Disorder and related conditions
  • A history of significant medical (e.g., cardiovascular, diabetic/metabolic) or neurological (e.g., cerebrovascular accidents, seizure, traumatic brain injury) illness
  • History of claustrophobia or feeling of inability to lie still on his/her back for the PET or MRI scans
  • History of any bleeding disorder or current anticoagulant therapy
  • History of kidney stones within the past 5 years
  • Any degree of renal failure
  • History of parathyroid disorder (hyper or hypoparathyroidism)
  • History of osteoporosis or any pathologic fractures
  • Known hypersensitivity to [11C]-PHNO or calcitriol
  • Malabsorption syndromes (i.e., Celiac sprue)
  • For females, laboratory (β-HCG) or physical evidence of pregnancy/lactation
  • Serum levels of 25(OH)D3 below 12 ng/ml
  • Serum corrected calcium > 10.5 mg/dl or phosphate > 4.2 mg/dL
  • Morbid obesity i.e., BMI over 35 (more prone to lower vitamin D levels)
  • Vitamin D supplementation in any form in the past 3 months

Where in United States

  • Yale School of MedicineNew Haven, United States

About the trial

What the trial wants to find out

The research team is investigating Opioid Use Disorder (OUD), a disorder characterized by dysregulated dopaminergic tone, to evaluate the mechanisms of adjunctive treatment with calcitriol. The investigators will recruit 12 subjects with OUD and 12 healthy subjects to participate in a double-blind, randomized study design where subjects will complete up to 2 Positron Emission Tomography (PET) scans using [11C]-PHNO. The investigators will compare subjects in differences between their own study days and in differences between healthy control subjects and subjects with OUD.

The 2 groups in the trial

  • CalcitriolExisting treatment, for comparison

    Subjects with OUD will receive a baseline MRI. On the night before and day of testing, subjects with OUD will receive two doses of calcitriol (3.0mcg total), followed by PHNO injection and PET Scan for the calcitriol condition. All subjects will complete the study with both active calcitriol and a placebo control and the order these interventions are received will be randomized.

    Treatment: [11C]-PHNO, Calcitriol, and PET Scan

  • PlaceboPlacebo, for comparison

    Subjects with OUD will receive a baseline MRI. On the night before and day of testing, subjects with OUD will receive two doses of an inactive placebo, followed by PHNO injection and PET Scan for the placebo condition. All subjects will complete the study with both active calcitriol and a placebo control and the order these interventions are received will be randomized.

    Treatment: [11C]-PHNO, Placebo Control, and PET Scan

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Exploration of Baseline Alterations on the Dopamine D2/D3 Receptor System and the Effects of Vitamin D in Opioid Use Disorder: an [11C]-PHNO Study
Record updated
14 November 2025